<DOC>
	<DOC>NCT02554565</DOC>
	<brief_summary>Quantification and follow-up of circulating tumoral DNA in serum and/or plasma of patients with cervical cancer compared to the early detection of minimal metastatic disease.</brief_summary>
	<brief_title>Nnovation for Standard Identification of Insertional HPV Mutations and of Target Therapeutic Genes in Cervical Cancer: Towards Development of Personalized Biomarkers in Clinical Oncology</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>1. Patient with cervical cancer, at any stage, before any antitumoral treatment. 2. Age â‰¥ 18 years. 3. Patient information and signature of the informed consent or her/his legal representative. 4. Patient having given her/his agreement for a second biopsy at diagnosis if the first one was performed outside of the center and was not cryopreserved. 1. Person deprived of liberty or under supervision. 2. Inability to attend scheduled followup visits for any psychological, sociological or geographical reasons.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Patients with cervical cancer</keyword>
</DOC>